Tag
The Phase 2 TREASURE trial investigated the safety and efficacy of adding consolidative thoracic radiotherapy to atezolizumab maintenance in extensive-stage small cell lung cancer, revealing increased toxicity without survival benefit, unde
A nationwide Japanese real-world study suggests that a defined body surface area–adjusted bevacizumab exposure range may improve progression-free and overall survival in unresectable HCC treated with atezolizumab plus bevacizumab, without i
The Phase II TAPISTRY trial evaluates atezolizumab in patients with high tumor mutational burden (TMB ≥13 or ≥16 mut/Mb), showing an objective response rate of approximately 20-22% across various solid tumors with a manageable safety profil
The phase III ALBAN trial found no benefit in adding atezolizumab to BCG for BCG-naive high-risk NMIBC, emphasizing that immunotherapy benefits in this space are likely agent-specific and necessitate better biomarker-driven selection.
Two randomized phase III trials tested adding atezolizumab to bevacizumab plus chemotherapy in recurrent ovarian cancer. Neither AGO‑OVAR 2.29/ENGOT‑ov34 (non‑platinum, platinum‑resistant) nor ATALANTE/ENGOT‑ov29 (platinum‑sensitive) met th
Phase 3 TALENTop trial interim results show liver resection following atezolizumab plus bevacizumab induction significantly prolongs time to treatment failure in advanced HCC without extrahepatic spread.
A French nationwide cohort study reveals no significant differences in effectiveness or safety between atezolizumab and durvalumab as first-line PD-L1 inhibitors combined with chemotherapy for extensive-stage small cell lung cancer.
A recent phase II trial demonstrates lenvatinib’s efficacy and manageable safety as a second-line treatment for unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab.
Atezolizumab maintenance therapy after multimodal definitive treatment failed to improve event-free or overall survival in high-risk LA SCCHN patients in the phase 3 IMvoke010 trial, highlighting challenges in immunotherapy for this setting
This review synthesizes pivotal evidence from the IMvigor011 trial demonstrating that ctDNA-guided adjuvant atezolizumab significantly improves disease-free and overall survival in muscle-invasive bladder cancer, enabling risk-adapted immun
The IMforte phase 3 trial demonstrates that lurbinectedin plus atezolizumab as first-line maintenance significantly prolongs progression-free and overall survival in extensive-stage small-cell lung cancer, albeit with increased hematologic
The CONTACT-02 phase 3 trial shows cabozantinib plus atezolizumab improves progression-free survival but not overall survival in advanced mCRPC post-ARPI, offering a novel non-androgen receptor-based option.
